Canaccord Genuity Reiterates a 'Buy' on Heartware Int'l (HTWR); Huge Q1 on Top Share in OUS
Tweet
Share
E-mailGet Alerts HTWR Hot Sheet
Price: $57.98 --0%
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 13 | New: 9
Rating Summary:
5 Buy, 14 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 4 | Down: 13 | New: 9
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Heartware Int'l (NASDAQ: HTWR) price target raised from $95 to $101.
Analyst, Jason R. Mills, said, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."
"We raise our 2012 sales/loss per share (LPS) estimates to $134.4M/$(4.65) from $125.5M/$(5.06)."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $77.14 yesterday.
Analyst, Jason R. Mills, said, "With HTWR crushing Q1 results, taking over the #1 LVAD share position OUS for the first time, and offering a plethora of potentially favorable upcoming catalysts (FDA approval and launch, first in man for MVAD, GLP studies for fully-implantable device), we reiterate HTWR as one of our best ideas for 2012. HTWR crushed our/consensus Q1 estimates, with OUS HVAD sales growing over 60% Y/Y, and eclipsing our estimate by ~50%. Currently in discussions with FDA on HVAD labeling and a post-approval study, HTWR is seemingly on track to hit our launch estimate of September."
"We raise our 2012 sales/loss per share (LPS) estimates to $134.4M/$(4.65) from $125.5M/$(5.06)."
For an analyst ratings summary and ratings history on Heartware Int'l click here. For more ratings news on Heartware Int'l click here.
Shares of Heartware Int'l closed at $77.14 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Jazz Pharmaceuticals (JAZZ) PT Raised to $310 at Needham
- Citi Downgrades Yang Ming Marine Transport Corp (2609:TT) to Neutral
- Citi Downgrades China COSCO Holdings (1919:HK) (CICOY) to Neutral
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
